SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Sentrian™
(formally Jointly Health), the Remote Patient Intelligence™ company
aspiring to eliminate all preventable hospitalization, formally
launched today at Singularity University's Exponential Medicine
Conference.
"Millions of unnecessary hospitalizations that endanger patients
and cost tens of billions of dollars every year could be avoided if
we could spot deterioration in patients' health earlier using
remote patient monitoring analytics," said Dean Sawyer, Co-Founder and CEO of Sentrian,
headquartered in Aliso Viejo,
California. "Our platform leverages the exponential growth
in biosensors and machine-learning and is intended to detect the
subtle signs that warn of an impending problem before the patient
becomes acute and requires hospitalization."
Peter Diamandis, Founder and Chairman of the X Prize Foundation,
Co-Founder of Singularity University, and named one of "The
World's 50 Greatest Leaders" by Fortune magazine, said, "The
idea for Sentrian was born out of one of the first Singularity
University Executive Programs and is a great example of how small
teams leveraging accelerating technologies can make a massive
impact. Sentrian is very well positioned to impact the problem of
chronic disease, which is crippling economies and causing an
unquantifiable amount of human suffering."
$12 million from multiple
investors
Sentrian has raised $12
million in financing including $4
million in seed funding and $8
million in a recent Series A round led by Reed Elsevier
Ventures, Frost Data Capital and TELUS Ventures.
"As healthcare moves from volume to value-based reimbursement,
tackling preventable hospital admissions becomes an imperative,"
said Kevin Brown, General Partner of
Reed Elsevier Ventures. "Sentrian has assembled a dream team
of entrepreneurs, technologists and physicians and has developed
the only analytics platform we've seen capable of taking advantage
of multivariate remote patient monitoring sensor data at scale. I
am thrilled to be joining the Sentrian team as an investor and
board member."
Jack Kreindler, MD, Sentrian's
Founder and Chief Medical Officer, said, "There is an
extraordinary opportunity and need today to apply
exponentially accelerating advances in biosensor technology and
human-augmented machine learning to finally make remote
patient management an affordable and effective reality for
patients, payers and providers alike. Sentrian is turning
the unprecedented stream of data from remote
sensors into foresight
and intelligence, bridging the chasm between
patients at home and providers in clinics and
hospitals – transforming the very way medicine
manages disease, and helping to solve a grand
challenge in healthcare."
Former IBM Research medical executive joins leadership
team
In addition to Sawyer, who is a former senior executive
of Allscripts and Physicians Interactive, Sentrian's leadership
team includes Chief Medical Scientist Martin Kohn, MD, MS, FACEP, a world-renowned
expert in healthcare population analytics and the role of expert
systems in the clinical decision process. Dr. Kohn was previously
the Chief Medical Scientist for Care Delivery Systems in IBM
Research, where he led IBM's support for the transformation of
healthcare, including the use of the Watson supercomputer in
healthcare.
Sentrian's platform is currently being tested by large health
insurance plans in controlled studies involving thousands of
patients. The company expects to announce the results of
those studies in 2015.
About Reed Elsevier Ventures
Reed Elsevier Group plc
is a world leading provider of professional information solutions.
The group employs approximately 28,000 people of whom half are in
North America. Reed Elsevier Group
PLC is owned equally by two parent companies, Reed Elsevier PLC and
Reed Elsevier NV; the combined market capitalisation of the two
parent companies is approximately £20bn/€25bn. Its shares are
traded on the London, Amsterdam and New York Stock Exchanges using
the following ticker symbols: London: REL; Amsterdam: REN; New
York: RUK and ENL.
About Sentrian
Sentrian™, the first Remote Patient
Intelligence™ company, aspires to eliminate all preventable
hospitalization by leveraging the revolution in remote biosensors
and machine learning to detect patient deterioration early, before
it becomes acute. Sentrian's value proposition to healthcare
organizations is to provide a cloud-based remote patient monitoring
and analytics platform intended to dramatically reduce preventable
hospital admissions, increase the efficiency and effectiveness of
care teams and improve quality metrics such as HEDIS and Star
ratings. The Sentrian platform is designed to seamlessly integrate
with existing healthcare information systems and clinical
workflows, facilitating adoption. Find us at www.sentrian.com, on
Twitter and LinkedIn.
CONTACT:
Joy
DiNaro
Amendola Communications for Sentrian
847.809.0406
Joy.DiNaro@acmarketingpr.com
Logo - http://photos.prnewswire.com/prnh/20141031/155906LOGO
SOURCE Sentrian